Tavapadon as a Novel Partial D1/D5 Selective Dopamine Agonist in Parkinson's Disease

This section highlights the emerging dopamine agonist tavapadon and its potential advantages in the treatment of Parkinson’s disease. Unlike traditional dopamine agonists that stimulate D2/D3 receptors, tavapadon selectively targets D1 and D5 receptors with partial agonist activity, which may reduce adverse effects linked to D3 activation such as impulse control disorders and sleep attacks. Early clinical research suggests that this mechanism may also improve motor control and potentially reduce dyskinesia compared with existing dopamine agonists. The speaker also notes that D5 receptor activity may provide additional benefits related to cognition, memory, mood, and reduced apathy, though these effects require further study. Overall, the development of more receptor-selective dopamine agonists such as tavapadon is generating excitement as they may deliver dopamine-related benefits with fewer side effects and efficacy potentially comparable to levodopa.